12/1
07:13 am
autl
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]
Low
Report
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]
12/1
07:00 am
autl
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
Low
Report
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
11/25
04:00 am
autl
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (=26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
High
Report
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (=26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
11/15
07:05 pm
autl
Autolus Therapeutics plc (NASDAQ:AUTL) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Medium
Report
Autolus Therapeutics plc (NASDAQ:AUTL) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/14
10:32 am
autl
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline [Seeking Alpha]
Low
Report
Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline [Seeking Alpha]
11/12
04:32 pm
autl
Autolus Therapeutics PLC (AUTL) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
Autolus Therapeutics PLC (AUTL) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
11/12
03:12 pm
autl
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
08:21 am
autl
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]
Neutral
Report
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]
11/12
07:06 am
autl
Autolus Therapeutics GAAP EPS of -$0.30 misses by $0.08, revenue of $21.14M misses by $0.17M [Seeking Alpha]
Low
Report
Autolus Therapeutics GAAP EPS of -$0.30 misses by $0.08, revenue of $21.14M misses by $0.17M [Seeking Alpha]
11/12
07:00 am
autl
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
11/11
08:00 am
autl
Santa Ana Bio Announces the Appointment of Mike Bonney as Chair of the Board
Medium
Report
Santa Ana Bio Announces the Appointment of Mike Bonney as Chair of the Board
11/3
12:15 pm
autl
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
11/3
09:05 am
autl
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
Low
Report
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
11/1
08:28 am
autl
Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade) [Seeking Alpha]
Low
Report
Autolus: Good Product, But Tricky Market Dynamics (Rating Downgrade) [Seeking Alpha]
10/30
11:45 pm
autl
Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential? [Yahoo! Finance]
Low
Report
Why is Autolus Therapeutics plc (AUTL) One of the Best Stocks Under $5 With Highest Upside Potential? [Yahoo! Finance]
10/30
07:00 am
autl
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Low
Report
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
10/28
05:31 pm
autl
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
10/28
05:31 pm
autl
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
10/27
07:00 am
autl
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
Medium
Report
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
10/24
12:16 pm
autl
Autolus Therapeutics (NASDAQ:AUTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Autolus Therapeutics (NASDAQ:AUTL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/20
08:08 am
autl
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
Low
Report
Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.
10/20
07:00 am
autl
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
Low
Report
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
10/15
04:05 pm
autl
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/6
05:31 pm
autl
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
10/6
05:31 pm
autl
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
Medium
Report
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight